XERS Earnings & Financial Statements
Xeris Biopharma Holdings, Inc.
$16.66
+$0.14(+0.85%)
63
Overall
40
Value
83
Tech
68
Quality
Market Cap
$3.04B
Volume
777.98K
52W Range
$5.25 - $15.21
Target Price
$14.00
XERS earnings and financial statements: Xeris Biopharma Holdings, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
XERS Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2023 | 2023 |
|---|---|---|---|---|---|
| Revenue | $291.85M | $203.07M | $163.91M | - | $33.20M |
| Cost of revenue | $42.57M | $36.83M | $28.64M | - | - |
| Operating income | $24.90M | -$33.65M | -$44.01M | - | -$7.96M |
| EBITDA | $42.33M | -$10.99M | -$21.53M | -$13.99M | -$9.21M |
| Net income | $554.0K | -$54.84M | -$62.26M | - | -$16.83M |
| EPS (diluted) | - | $-0.37 | $-0.45 | - | $-0.12 |
| Fiscal year | 2025 | 2024 | 2023 | 2023 | 2023 |
|---|---|---|---|---|---|
| Total assets | $383.53M | $323.06M | $322.60M | - | $321.36M |
| Total liabilities | $369.84M | $352.68M | $329.38M | - | $291.31M |
| Shareholders’ equity | $13.69M | -$29.61M | -$6.78M | - | $30.05M |
| Cash and equivalents | $111.04M | $71.62M | $67.45M | - | $50.98M |
| Long-term debt | $251.87M | $250.26M | $225.70M | - | $196.97M |
| Fiscal year | 2025 | 2024 | 2023 | 2023 | 2023 |
|---|---|---|---|---|---|
| Operating cash flow | $28.63M | -$36.98M | -$47.02M | - | -$26.14M |
| Capital expenditure | -$696.0K | - | - | - | -$238.0K |
| Free cash flow | $27.93M | -$36.98M | -$47.02M | -$41.67M | -$26.38M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XERS | $16.66 | +0.8% | 777.98K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Xeris Biopharma Holdings, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW